60
Participants
Start Date
August 31, 2003
Primary Completion Date
September 30, 2004
Study Completion Date
September 30, 2004
Vernakalant Injection 20 mg/mL
Medical College of Virginia, Richmond
McGuire VA Medical Center, Richmond
Thoracic and Cardiovascular Institute, Lansing
Marshfield Clinic, Marshfield
Regional Cardiology Associates, Sacramento
Heart Health Institute, Rockyview General Hospital, Calgary
University of Calgary, Calgary
University of Alberta Hospital, Edmonton
Hamilton Health Sciences, Hamilton General Hospital, Hamilton
Ottawa Hospitals (Civic & General), Ottawa
Institut de Cardiologie de Montreal, Montreal
Hopital Notre-Dame du CHUM, Montreal
CHUM-Hotel-Dieu de Montreal, Montreal
Aalborg University, Aalborg
H:S Bispebjerg Hospital, Copenhagen
Centralsygehuset Esbjerg Varde, Esbjerg
Glostrup Amtssygehus, Glostrup Municipality
Gentofte Amtssygehus, Hellerup
Herlev Amtssygehus, Kardiologisk, Herlev
Sygehus Vendsyssel Hjorring, Hjørring
Holstebro centralsygehus, Holstebro
Hvidovre Hospital, Kardiologisk, Hvidovre
Universitetssjukhuset MAS, Malmo
Centrallasarettet, Vasteras, Västerås
Lead Sponsor
Astellas Pharma US, Inc.
INDUSTRY
Advanz Pharma
INDUSTRY